‘Best expectation’: Vaccine responses may prevent, delay cancer relapse
A personalized cancer vaccine produced T-cell responses in certain patients with head and neck squamous cell carcinoma, according to results from a randomized study presented at American Association for Cancer Research Annual Meeting.None of the patients treated with the novel vaccine, TG4050, have gone into remission, with one currently at 36 months relapse free.